A study by Wegrzynowicz and colleagues used a transgenic mouse line (MI2) which expressed human, aggregation-prone truncated 1–120 alpha-synuclein and control mice to investigate alpha-synuclein pathology in PD [18]. This evidence concerns the gene SNCA and Parkinson disease.